Asymptomatic Alzheimer disease

Timothy J. Hohman, Donald G. McLaren, Elizabeth C. Mormino, Katherine A. Gifford, David J. Libon, Angela L. Jefferson

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Objective: To define robust resilience metrics by leveraging CSF biomarkers of Alzheimer disease (AD) pathology within a latent variable framework and to demonstrate the ability of such metrics to predict slower rates of cognitive decline and protection against diagnostic conversion. Methods: Participants with normal cognition (n = 297) and mild cognitive impairment (n = 432) were drawn from the Alzheimer's Disease Neuroimaging Initiative. Resilience metrics were defined at baseline by examining the residuals when regressing brain aging outcomes (hippocampal volume and cognition) on CSF biomarkers. A positive residual reflected better outcomes than expected for a given level of pathology (high resilience). Residuals were integrated into a latent variable model of resilience and validated by testing their ability to independently predict diagnostic conversion, cognitive decline, and the rate of ventricular dilation. Results: Latent variables of resilience predicted a decreased risk of conversion (hazard ratio < 0.54, p < 0.0001), slower cognitive decline (β > 0.02, p < 0.001), and slower rates of ventricular dilation (β < -4.7, p < 2 × 10 -15). These results were significant even when analyses were restricted to clinically normal individuals. Furthermore, resilience metrics interacted with biomarker status such that biomarker-positive individuals with low resilience showed the greatest risk of subsequent decline. Conclusions: Robust phenotypes of resilience calculated by leveraging AD biomarkers and baseline brain aging outcomes provide insight into which individuals are at greatest risk of short-term decline. Such comprehensive definitions of resilience are needed to further our understanding of the mechanisms that protect individuals from the clinical manifestation of AD dementia, especially among biomarker-positive individuals.

Original languageEnglish (US)
Pages (from-to)2443-2450
Number of pages8
JournalNeurology
Volume87
Issue number23
DOIs
StatePublished - Dec 6 2016

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Asymptomatic Alzheimer disease'. Together they form a unique fingerprint.

Cite this